Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador

scientific article published on October 1, 2010

Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3747/CO.V17I5.592
P953full work available at URLhttp://www.current-oncology.com/index.php/oncology/article/download/592/514
https://europepmc.org/articles/PMC2949362
https://europepmc.org/articles/PMC2949362?pdf=render
https://www.mdpi.com/1718-7729/17/5/592/pdf
P932PMC publication ID2949362
P698PubMed publication ID20975873
P5875ResearchGate publication ID47545259

P50authorGeorge DranitsarisQ92696583
P2093author name stringJ. Edwards
R. Abbott
S. Edwards
M. Leblanc
P2860cites workBevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Q56679480
Underrepresentation of patients 65 years of age or older in cancer-treatment trialsQ73311140
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction toolQ79802528
Participation in cancer clinical trials: race-, sex-, and age-based disparitiesQ80179103
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerQ27860681
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerQ28186303
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabQ28219257
A new method of classifying prognostic comorbidity in longitudinal studies: development and validationQ29547376
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to actionQ33561213
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.Q34590731
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisQ37328873
Diagnosis and initial treatment of venous thromboembolism in patients with cancerQ37593813
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trialQ44921373
Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysisQ45198180
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lunQ45309210
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapyQ46408279
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectcolorectal cancerQ188874
bevacizumabQ413299
chemotherapyQ974135
FOLFIRIQ1389369
metastatic colon cancerQ108566365
P304page(s)12-16
P577publication date2010-10-01
P1433published inCurrent OncologyQ3498968
P1476titleBevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador
P478volume17

Reverse relations

cites work (P2860)
Q33982704Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer
Q35230910Methyl tert butyl ether is anti-angiogenic in both in vitro and in vivo mammalian model systems
Q35230207Methyl tert butyl ether targets developing vasculature in zebrafish (Danio rerio) embryos
Q41472249Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients
Q45735669Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort

Search more.